International Isotopes Inc (INIS) (OTCQB:INIS), a US supplier of generic sodium iodide I-131 radio-pharmaceutical drug products for hyperthyroidism and thyroid cancer, announced on Wednesday that it has filed a Certificate of Amendment in the State of Texas to change its legal name to Radnostix Inc, effective immediately.
The company is planning to rebrand all its operations under the Radnostix name.
INIS was established in 1995 with a focus on irradiation and manufacturing of industrial radioisotope products. Its focus has evolved over the years, and the name change reflects the company's expanding product segments and evolving strategic focus on radioisotopes and theranostics products.
The INIS branding will be maintained in segments focused on high energy sources, bulk radioisotopes, and stable isotopes.
For the time being, the company's common stock will continue to trade under its current ticker symbol 'INIS' on the OTCQB marketplace.
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic